CMTM6 and lung carcinoma: In lung cancer patients, CMTM6 expression acts as a predictor of PD-1 inhibitor therapy; that is, patients with higher CMTM6 expression respond well to PD-1 inhibitors (Gao et al., 2019; Koh et al., 2019).